Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Vinorelbine and Cisplatin in Neoadjuvant HER2-negative Breast Cancer
NCT04848454Phase 2Unknown
- Sponsor
- Peking University First Hospital
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in breast cancer, sponsored by Peking University First Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04848454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848454.